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Introduction
Various reasons can lead to abortion in the second tri-
mester of pregnancy. Abortion in the second trimester of 
pregnancy causes significantly more complications like 
hemorrhage and placental retention as compared to the 
abortions occurring in gestational ages less than 8 weeks. 
In order to control and improve the third stage of labor, 
several medications derived from oxytocin, ergots, and 
prostaglandin groups can be used orally, vaginally, and 
rectally (1-5). Rectal, vaginal and oral misoprostol can 
be used for controlling hemorrhage in the third stage of 
delivery. Rectal administration of misoprostol has the ad-
vantage of having high level of absorption in the body and 
fewer complications in comparison to its oral form. Cases 
of retained placenta in different studies have been report-
ed between 8%-80% (6,7). The aim of this study was to 
compare the efficacy of intravenous oxytocin versus rectal 
misoprostol in the management of the third stage of labor 
during pregnancy termination.
Materials and Methods
In this randomized clinical trial, 100 women with ges-
tational age of 14-28 weeks, visiting for terminating the 
pregnancy due to intrauterine fetal death (IUFD) or ap-
proved premature rupture of membrane (PROM), entered 
the study. After being informed about the possible abor-
tion procedures, medications, side effects and methods 
of implementation, they completed the consent form and 
were divided into two groups of 50 patients each by ran-
dom selection methods (by selecting one of the red and 
blue cards). All women in the two groups (oxytocin and 
misoprostol) underwent the same protocol of receiving 
200 µg vaginal misoprostol every 6 hours. In case of hav-
ing cesarean, lower doses of misoprostol were adminis-
tered, which lasted for 24 hours, and if no response was 
received, it would be continued for the next 24 hours. Af-
ter 48 hours, while considering the condition of the cervix 
and its dilation, other methods such as putting catheter 
into the cervix or using high doses of oxytocin would be 
used.
After recording the time of fetal expulsion, intravenous 
oxytocin including 40 units of oxytocin in a liter of normal 
saline during one hour was administered to one group and 
400 µg of rectal misoprostol was administered to the other 
group. We had 1 hour to register the time of placenta ex-
pulsion and during this time the patients were monitored 
every 15 minutes and their vital signs including blood 
pressure, heart rate and the amount of bleeding based on 
the number of consumed pads, fever, chills, diarrhea and 
vomiting were checked and recorded.
If placental expulsion did not occur in an hour or the vital 
signs of mother were unstable, or vaginal bleeding was se-
vere, the patients would undergo curettage and the uterine 
contents would be removed and sent to pathology. In case 
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Introduction 
Throughout the history of the world, the ones who had 
confronted the bitterest face of poverty and war had al-
ways been the women. As known poverty and war affects 
human health either directly or indirectly, the effects of 
this condition on health and status of women in the so-
ciety should not be ignored. This study intends to cast 
light on the effects of war and poverty on the reproductive 
health of wome . For this purpose, the face f war affect-
ing the women, the problem of im igration, inequalities 
in dist ibution of income based o  ge der and the effects
of all these on the reproductive health of women will be 
addressed.
War and Women’s Health
Famine, synonymous with war and poverty, is clearer for 
women; war means deep disadvantages such as full de-
struction, loss of future and uncertainty for women. Wars 
are conflicts that destroy families, societies and cultures 
that negatively affect the health of community and cause 
violation of human rights. According to the data of World 
Health Organization (WHO) a d World B nk, in 2002 
wars had been among the first ten reasons which killed 
the most and caused disabilities. Civil l sses are at the rate 
of 90% within all losses (1).
War has many negative effects on human health. One of 
these is its effect of shortening the average human life. 
According to the data of WHO, the average human life is 
68.1 years for males and 72.7 years for females. It is being 
thought that severe military conflicts in Africa shorten 
the expected lifetime for more than 2 years. In general, 
WHO had calculated that 269 thousand people had died 
in 1999 due to the effect of wars and that loss of 8.44 mil-
lion healthy years of life had occurred (2,3).
Wars negatively affect the provision of health services. 
Health institutions such as hospitals, laboratories and 
health centers are direct targets of war. Moreover, the wars 
cause the migrati  of qualified health empl yees, and 
thus the he lth services hitches. Assessments made indi-
cate that the effect of destruction in the infrastructure of 
health continues for 5-10 years even after the finalization 
of conflicts (3). Due to resource requirements in the re-
structuring investments after war, the share allocated to 
health has decreased (1).
Mortalities and Morbidities
The ones who are most affected from wars are women and 
children. While deaths depending on direct violence af-
fect the male population, the indirect deaths kill children, 
women and elders more. In Iraq between 1990-1994, i -
fant deaths had shown this real y in its more bare form 
with an increase of 600% (4). The war taking five years 
increases the child deaths under age of 5 by 13%. Also 47% 
of all the refugees in the world and 50% of asylu  seekers 
and displaced people are women and girls and 44% ref-
ugees and asylum seekers are children under the age of 
18 (5).
As the result of wars and armed conflicts, women are 
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of placental delivery during 1 hour, the patient underwent 
ultrasonography to be examined for remains of pregnan-
cy. The time of fetal delivery, the time between fetal deliv-
ery and placental expulsion, and the amount of mother’s 
bleeding were recorded based on reduction of hemoglobin 
(before abortion and 24 hours after the abortion). The ex-
clusion criteria in this study were having allergy or intol-
erance to misoprostol, hypertension over 90/160 mm Hg, 
having severe cardiovascular disease, very bad patient’s 
general condition, history of previous uterine scar (except 
for having one transverse cesarean incision in the lower 
segment of uterine layer), presence of medical abortion 
contraindications like severe anemia, using anticoagulants 
or having coagulation disorders, active liver disease, un-
controlled seizure disorders, adrenal disease (Addison), 
disorders requiring treatment with corticosteroids and 
fetal removal via non-medical methods.
 
Statistical Analysis
Collected data were entered into SPSS version 20 and an-
alyzed using descriptive and analytical statistical methods 
such as chi-square test and t test for comparing the vari-
ables between the two groups. In all tests, the significance 
level was set at less than 0.05.
Results
In this study, the groups were not significantly different 
from each other in terms of demographic and medical in-
formation such as age, gestational age, hemoglobin levels 
at admission and other details related to the number of 
pregnancy (Table 1). As Table 2 displays, the frequency of 
retained placenta in the misoprostol group with 4 patients 
(8%) was less than the oxytocin group with 8 cases (16%), 
but not statistically significant. Most cases of retained pla-
centa in the oxytocin group and the misoprostol group re-
lates to gestational age less than 16 weeks with 4 patients 
(50%) and 3 cases (75%), respectively. Average time for 
placental expulsion was 19.8 ± 12 minutes in the oxytocin 
group and 21.4 ± 9.2 minutes in the misoprostol group and 
there was no statistically significant difference between 
the two groups. Comparing the remnants of pregnancy af-
ter the expulsion of the placenta via sonography revealed a 
significant difference between the two groups, i.e., 15 cas-
es (30%) in the misoprostol group and 30 cases (60%) in 
the oxytocin group.
Also, in cases with positive reports of ultrasound (15 cases 
[30%] in the misoprostol group and 29 cases [58%] in the 
oxytocin group), the presence of placenta confirmed by 
pathology was significantly different between two groups 
(P = 0.032). Serum hemoglobin level represented a signifi-
cant reduction in both groups after abortion. The amount 
of reduction in the oxytocin group with 0.8 units was sig-
nificantly higher than the misoprostol group with 0.54 
units (P = 0.001). The number of cases who underwent 
emergent curettage was 4 (8%), that occurred in the oxy-
tocin group due to excessive bleeding and changes in the 
mother’s vital signs, but no emergent curettage was seen 
in the misoprostol group. No drug side effects were seen 
in both groups with administered doses. The amount of 
bleeding based on the number of used pads did not differ 
significantly in the two groups.
Discussion
Retained placenta is one of the most significant compli-
cations in the result of abortions, which requires surgical 
intervention for removal. Some studies have reported the 
frequency of retained placenta after terminating pregnan-
cy with prostaglandins about 80% (8). Despite surgical 
intervention seems safer in termination of pregnancy, in 
cases in which abortion is induced because of fetal anom-
alies, it is accompanied by surgery risks and requires the 
surgeon’s dexterity (9).
Different studies, considering the experts’ suggestions, 
have used various protocols like intramuscular synto-
metrin (10), intravenous oxytocin (11), intramuscular 
PGF2α (12) and in some cases expected intervention and 
routine curettage have been recommended (10,13). To re-
duce the postpartum bleeding after delivery and to have 
less intervention in the third stage of labor, it is better to 
have active interventions in placental expulsion. In this 
study, the selected intervention was of the type that can be 
used in most of clinical cases.
Regarding the results of the present study, the duration 
of the placental expulsion in the rectal misoprostol group 
and intravenous oxytocin group was similar. The fre-
quency of cases with retained placenta in the misoprostol 
group with 4 (8%) was lower than the oxytocin group with 
8 (16%), but this difference was not statistically signifi-
cant. It is worth mentioning that the cost of misoprostol 
is less than oxytocin. 
Although the level of hemoglobin was decreased in both 
groups, greater decrease was seen in the oxytocin group. 
Misoprostol has several comparative advantages. There 
are some studies that have shown the effectiveness of 
misoprostol compared with oxytocin in inducing abortion 
Table 1. Demographic Information of Two Groups Before Study
Variables Misoprostol Oxytocin P
Mean age of mothers (year) 26.1 ± 4.5 27.2 ± 5.9 0.12
Hb 11.5 ± 1.2 11.8 ± 1.2 0.3
Gestational age 18.6 ± 3.7 18.2 ± 3.6 0.57
Placental expulsion time (min) 21.4 ± 9.2 19.8 ± 12 0.45
Table 2. Comparison of Variables Between Two Groups
Variables Misoprostol, No. (%)
Oxytocin, No. 
(%) P
Retained placenta 4 (8) 8 (16) 0.21
Remains of pregnancy after 
ultrasound
15 (30) 30 (60) 0.003
Emergent curettage 0 (0) 4 (8) 0.039
Bleeding 0.37
Excessive 1 (2) 1 (2)
Moderate 27 (54) 20 (40)
Heavy 22 (44) 29 (58)
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and have reported lower percentage of retained placenta 
(2% vs. 15%) (14). The same pattern was observed in the 
present study (8% vs. 16%), and the slight difference be-
tween the results can be attributed to the larger sample 
size and to selecting population according to different cri-
teria in other studies. In general, conducted studies have 
reported lower level of retained placenta in patients that 
had used misoprostol for abortion (10).
The present study revealed the superiority of rectal 
misoprostol regimen over intravenous oxytocin. Pre-
viously, other studies had shown similar results for oral 
misoprostol (15).
Contrary to our findings, some studies have reported that 
the percentage of retained placenta and the amount of 
bleeding in the intervention group of oxytocin were sig-
nificantly lower in the intramuscular oxytocin group (10). 
However, due to the easy use of misoprostol and its lower 
price and stability at room temperature, it seems reason-
able to be employed in the interventions of the third stage 
of labor. The controversy among study’ results is likely to be 
because of various methods used for inducing abortions, 
different doses and methods and finally diverse inclusion 
and exclusion criteria in different hospitals. While in the 
studies of Parsons et al and Mansouri et al, no difference 
was found between the effectiveness of rectal misoprostol 
and intravenous oxytocin, they suggested administering 
it, particularly in the less developed countries, because of 
the above mentioned reasons. Additionally, in a clinical 
trial that compared the effectiveness of rectal misoprostol 
with oxytocin accompanied by methyl ergometrin, the lat-
ter showed better results (16,17). 
Some studies have shown that acceptable time for pla-
cental expulsion in the third stage of labor can last up to 
six hours (8,9). In this study, in both groups, on average, 
placental expulsion occurred in less than one hour. This 
shows the positive effect of intervention in the third stage 
of labor which can significantly decrease its complica-
tions through considerable reduction in the duration of 
placental removal. It seems that in case of complications, 
interventional approach should be preferred to expected 
approach. Although in respect of the pharmacokinetics, 
misoprostol can be absorbed via different ways (rectally or 
vaginally), but their similar final effect is confirmed (18). 
In the present study, 400 µg rectal misoprostol regime was 
used, which was found clinically effective. A clinical trial 
in 2003, showed the efficacy of rectal misoprostol and its 
lower bleeding and complications as compared to other 
regimes (19).
It was also reported that 800 µg of rectal misoprostol can 
reduce bleeding during cesarean in comparison with in-
travenous oxytocin which was similar to the findings of 
this study.
Conclusion
Results showed that the use of rectal misoprostol in the 
third stage of abortion in the second trimester of pregnan-
cy can be effective as compared to intravenous oxytocin, 
in reducing the amount of bleeding and retained products 
of conception and placenta and the number of cases re-
quiring emergent curettage.
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